Sign up
Pharma Capital
EPIC: ZYNE
Market: NASDAQ
Sector: Pharma & Biotech
Website:

At Zynerba Pharmaceuticals, we are dedicated to developing next-generation synthetic cannabinoid therapeutics for transdermal delivery for patients with high unmet medical needs.
Our mission is to improve the lives of patients battling severe health conditions including epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain through these therapeutics.
Our development pipeline includes patent-protected synthetic transdermal cannabinoid products, which we believe will provide new treatment options for patients as well as additional treatment options for patients not currently receiving adequate relief or otherwise experiencing intolerable side effects from current treatment regimes.

Zynerba Pharmaceuticals

Interactive graph

col 3
col 4
col 5
col 6

Zynerba Pharmaceuticals Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.